Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adjuvant therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,749 result(s) found for: Adjuvant therapy. Displaying page 1 of 88.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-005181-30 Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 Start Date*: 2015-07-09
    Sponsor Name:ABCSG GmbH
    Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor...
    Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2013-003839-30 Sponsor Protocol Number: D081CC00006 Start Date*: 2014-06-16
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germl...
    Medical condition: Adjuvant breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) AT (Trial now transitioned) IS (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004362-26 Sponsor Protocol Number: I3Y-MC-JPCF Start Date*: 2017-08-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, ...
    Medical condition: Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-000566-38 Sponsor Protocol Number: R2810-ONC-1788 Start Date*: 2019-10-04
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
    Medical condition: Patients with features associated with high-risk of recurrent CSCC disease, who have completed surgery and post-operative RT radiation therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003064-27 Sponsor Protocol Number: PH-L19IL2TNF-01/18 Start Date*: 2022-02-25
    Sponsor Name:Philogen S.p.A.
    Full Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and ...
    Medical condition: Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001908-17 Sponsor Protocol Number: 2021.40 Start Date*: 2022-09-05
    Sponsor Name:Leiden University Medical Center
    Full Title: Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroid (NEO-ATACT study)
    Medical condition: BRAF-mutated anaplastic thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10043745 Thyroid neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002079-17 Sponsor Protocol Number: ICO-N-2017-14 Start Date*: 2018-10-16
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Evaluation of the 64Cu-ATSM PET-CT as a predictor of the response to neo-adjuvant treatment in locally advanced rectal cancers
    Medical condition: men and / or women older than 18, newly diagnosed for locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001488-60 Sponsor Protocol Number: WSG-AM11 Start Date*: 2020-07-09
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus stand...
    Medical condition: HR+/HER2- early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004693-27 Sponsor Protocol Number: A6181064 Start Date*: 2006-11-09
    Sponsor Name:Pfizer Ltd.
    Full Title: A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS
    Medical condition: Advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) AT (Prematurely Ended) SE (Prematurely Ended) FI (Completed) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003739-22 Sponsor Protocol Number: GAL-01-2007 Start Date*: 2007-10-04
    Sponsor Name:GALSOR S.R.L.
    Full Title: Safety and efficacy (for the symptom remission) of the treatment adjuvant of the antibiotic therapy of the acute episode of sinusitis (acute, subacute, chronic)with Ecballium Elaterium (SINUclean D...
    Medical condition: Acute sinusitis or exacerbation of subacute or chronic sinusitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040753 Sinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005350-79 Sponsor Protocol Number: NN028-1801 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: A single arm, single-centre, open-label, exploratory trial of recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymp...
    Medical condition: Recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymph node dissection followed by 8 weeks of adjuvant treatment in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020480-21 Sponsor Protocol Number: pro-duct001 Start Date*: 2010-11-18
    Sponsor Name:Universitätsmedizin Charite
    Full Title: Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer
    Medical condition: proximal bile duct cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000935-15 Sponsor Protocol Number: PRODIGE70-CIRCULATE Start Date*: 2019-09-10
    Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon
    Full Title: CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
    Medical condition: stage II colon cancer, after tumour resection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000185-22 Sponsor Protocol Number: 20110265 Start Date*: 2014-12-03
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma
    Medical condition: Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Prematurely Ended) BE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) GR (Completed) IT (Prematurely Ended) FI (Prematurely Ended) CZ (Completed) PT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001974-76 Sponsor Protocol Number: MK-3475-630 Start Date*: 2019-01-16
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Adv...
    Medical condition: Resectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000129-28 Sponsor Protocol Number: GO42784 Start Date*: 2021-08-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004266-40 Sponsor Protocol Number: ICORG 06-32/NSABP B-42 Start Date*: 2007-11-02
    Sponsor Name:ICORG
    Full Title: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxife...
    Medical condition: Hormone Receptor Positive Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000575-27 Sponsor Protocol Number: MK-3475-091-05 Start Date*: 2015-09-17
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy...
    Medical condition: Stage IB (T ≥ 4 cm), II and IIIA NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2015-005322-19 Sponsor Protocol Number: MIND-DC Start Date*: 2016-01-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: A randomized, double-blind, placebo-controlled phase III study to evaluate active immunization in adjuvant therapy of patients with stage IIIB and IIIC melanoma with natural dendritic cells pulsed ...
    Medical condition: melanoma patients with regional lymph node metastases (stage III)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:52:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA